Cancer

06

Jan 2020

At the start of the organized program for the early detection of cervical cancer on January 1, 2020, several new services will be added to the EBM (Einheitlicher Bewertungsmaβstab, German Uniform Evaluation Standard). Read more

26

Dec 2019

In late November 2019, the network of European HTA agencies, EUnetHTA, announced the final plan of the project OTCA23 “Biodegradable rectum spacers to reduce toxicity for prostate cancer.” Read more

24

Dec 2019

In November 2019, the National Institute for Health and Care Excellence (NICE) published two new diagnostics guidance (for point-of-care creatinine devices and rapid tests for group A streptococcal infections), one new interventional procedure guidance (for irreversible electroporation for primary liver cancer) and two new MedTech innovation briefings (for Leukomed Sorbact for preventing surgical site infection and AmnioSense for unexplained vaginal wetness in pregnancy). Read more

23

Dec 2019

On the 10th of December 2019, the Austrian HTA body, the Ludwig-Boltzmann Institute (LBI-HTA) has released a report on the implementation of an HPV screening test for the early detection of cervical cancer in women as a measure of cervical cancer prevention. The recommendations are positive. Read more

19

Dec 2019

In late November 2019, new HTA activities were published on the website of regional HTA program of Lombardy Region, after a period of inactivity. Twenty-six (26) new technologies are currently in various stages of the HTA process, and they should all be completed in 2020. Read more

03

Dec 2019

In October 2019, the Agency for Health Quality and Assessment of Catalonia (AQuAS) has released an assessment report regarding the scientific evidence on personalized population screening for breast cancer. The current evidence does not allow to recommend any concrete models for individualized risk prediction for breast cancer but allows to recommend the development and evaluation of new models for personalized risk prediction directed to offering different strategies to the screening of population. Read more

15

Nov 2019

In September 2019, the French High Authority for Health released an assessment report for analysis on DNA chips (ACPA) in different types of oncological conditions to determine its place in comparison with more conventionally used techniques. The ACPA allows to detect a large number of copy number of variations at the whole genome level, ploidy abnormalities, and heterozygosity losses; it is of interest as a cytogenetic technique with some specific advantages among existing technologies. Read more

02

Oct 2019

In August 2019, the Norwegian Institute of Public Health has released an HTA report regarding the effectiveness of treatment for localized prostate cancer commissioned by the Centre for joint decision-making to summarize the findings regarding this method. The effectiveness of the several treatment methods is unknown due to the lack of evidence. There is little or no difference in survival after radical prostatectomy compared to low-dose-rate brachytherapy. Read more

27

Sep 2019

In August 2019, the Norwegian Institute of Public Health (NIPH) has released a single technology assessment report for molecular profiling panel – Prosigna aimed to investigate its prognostic accuracy, clinical and cost-effectiveness in patients with breast cancer. It was outlined that it is uncertain to what extent Prosigna contributes prognostic information that turns into better clinical results; conclusions about the cost-effectiveness of Prosigna cannot be made due to the lack of existing information. Read more

24

Sep 2019

In August 2019, the National Institute for Health and Care Excellence published one new MedTech innovation briefings for vacuum therapy for colorectal anastomotic leakage and two new interventional procedure guidance for endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms and the Papillon technique for locally advanced rectal cancer. Read more

01

Aug 2019

Predictive Analysis for Therapy (PATH) is a major collaborative project to optimize molecular predictive diagnostics in the Netherlands. The project focuses on the molecular analyses that are important for the treatment choice of cancer patients. Read more